정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1157 | Not yet recruiting | Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial | Covid19 | Biological: intravenous immunoglobulin therapy | Phase 3 | University of Health Sciences Lahore, University of Lahore, Amson Vaccine and Pharma (Pvt) Limited | OTHER | 60 | All | 18 Years ~ 90 Years | University of Health Sciences, Lahore, Punjab, Pakistan |
| 1156 | Recruiting | Intravenous Infusion of CAP-1002 in Patients With COVID-19 | Covid19 | Biological: CAP-1002 Biological: Placebo |
Phase 2 | Capricor Inc. | INDUSTRY | 60 | All | 18 Years | Cedars-Sinai Medical Center, Los Angeles, California, United States University of California Davis, Sacramento, California, United States Henry Ford Health System, Detroit, Michigan, United States PharmaTex Research, LLC, Amarillo, Texas, United States |
| 1155 | Recruiting | Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness | Acute Hypoxemic Respiratory Failure | Drug: L-Citrulline Drug: Placebo |
Phase 2 | Asklepion Pharmaceuticals, LLC | INDUSTRY | 66 | All | 18 Years ~ 65 Years | University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States |
| 1154 | Recruiting | Intravenous Zotatifin in Adults With Mild or Moderate COVID-19 | Corona Virus Infection | Drug: Zotatifin Drug: Placebo |
Phase 1 | Effector Therapeutics, Medpace, Inc. | INDUSTRY | 36 | All | 18 Years ~ 64 Years | Synergy Healthcare, Bradenton, Florida, United States Global Health Research Center, Miami Lakes, Florida, United States Tampa General Hospital, Tampa, Florida, United States National Institutes of Health Clinical Center, Bethesda, Maryland, United States |
| 1153 | Active, not recruiting | Investigating a Vaccine Against COVID-19 | Coronavirus | Biological: ChAdOx1 nCoV-19 (Abs 260) Biological: MenACWY vaccine Biological: ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost Biological: Two dose MenACWY vaccine Biological: ChAdOx1 nCoV-19 (qPCR) Biological: ChAdOx1 nCoV-19 0.5mL prime plus boost Biological: Two dose MenACWY vaccine min. 4 weeks apart Biological: Two dose ChAdOx1 nCoV-19/Covishield 0.5mL Biological: Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL |
Phase 3 | University of Oxford | OTHER | 12390 | All | 18 Years | University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom Castle Hill Hospital, Cottingham, Hull, United Kingdom St Georges University Hospital NHS Foundation Trust, London, Tooting, United Kingdom University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom North Bristol NHS Trust, Bristol, United Kingdom NIHR Cambridge Clinical Research Facility, Cambridge, United Kingdom NHS Lothian, Western General Hospital, Edinburgh, United Kingdom Glasgow University and NHS Greater Glasgow & Clyde, New Lister Building, Glasgow Royal Infirmary & Queen Elizabeth University Hospital, Glasgow, United Kingdom Liverpool School of Tropical Medicine (LSTM), Accelerator Research Clinic. Clinical Sciences Accelerator, LIverpool, United Kingdom London North West University Healthcare Trust (LNWUH), Northwick Park Hospital, London, United Kingdom University College London Hospitals NHS Foundation Trust, London, United Kingdom Guy's and St Thomas' NHS Foundation Trust, Department of Infection, St Thomas Hospital, London, United Kingdom Imperial College Healthcare NHS Trust, London, United Kingdom The Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom Public Health Wales, Newport, United Kingdom University of Nottingham Health Service, Cripps Health Centre, University Park, Nottingham, United Kingdom CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom John Radcliffe Hospital, Oxford, United Kingdom Sheffield Teaching Hospitals, Royal Hallamshire Hospital, Sheffield, United Kingdom |
| 1152 | Enrolling by invitation | Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial | Coronavirus Infections | Biological: Convalescent Plasma | Not Applicable | Mazandaran University of Medical Sciences | OTHER | 30 | All | 30 Years ~ 70 Years | Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran, Islamic Republic of |
| 1151 | Completed | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | Severe Acute Respiratory Syndrome | Biological: Otilimab Biological: Placebo 1 Biological: Placebo 2 Drug: Standard of care |
Phase 2 | GlaxoSmithKline | INDUSTRY | 1156 | All | 18 Years | GSK Investigational Site, Mobile, Alabama, United States GSK Investigational Site, Little Rock, Arkansas, United States GSK Investigational Site, Sacramento, California, United States GSK Investigational Site, Torrance, California, United States GSK Investigational Site, Gainesville, Florida, United States GSK Investigational Site, Winfield, Illinois, United States GSK Investigational Site, Baltimore, Maryland, United States GSK Investigational Site, Germantown, Maryland, United States GSK Investigational Site, Silver Spring, Maryland, United States GSK Investigational Site, Saint Louis Park, Minnesota, United States GSK Investigational Site, Saint Paul, Minnesota, United States GSK Investigational Site, Jackson, Mississippi, United States GSK Investigational Site, Reno, Nevada, United States GSK Investigational Site, Buffalo, New York, United States GSK Investigational Site, Charlotte, North Carolina, United States GSK Investigational Site, Toledo, Ohio, United States GSK Investigational Site, Doylestown, Pennsylvania, United States GSK Investigational Site, Philadelphia, Pennsylvania, United States GSK Investigational Site, Roanoke, Virginia, United States GSK Investigational Site, Tacoma, Washington, United States GSK Investigational Site, Milwaukee, Wisconsin, United States GSK Investigational Site, Munro, Buenos Aires, Argentina GSK Investigational Site, Cordoba, Cordova, Argentina GSK Investigational Site, Buenos Aires, Argentina GSK Investigational Site, Buenos Aires, Argentina GSK Investigational Site, Cordoba, Argentina GSK Investigational Site, Cordoba, Argentina GSK Investigational Site, Brussel, Belgium GSK Investigational Site, Yvoir, Belgium GSK Investigational Site, Belo Horizonte, Minas Gerais, Brazil GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil GSK Investigational Site, Sao Paulo, Brazil GSK Investigational Site, Sao Paulo, Brazil GSK Investigational Site, Sao Paulo, Brazil GSK Investigational Site, Sao Paulo, Brazil GSK Investigational Site, Vancouver, British Columbia, Canada GSK Investigational Site, Ottawa, Ontario, Canada GSK Investigational Site, Ottawa, Ontario, Canada GSK Investigational Site, Montreal, Quebec, Canada GSK Investigational Site, QC, Quebec, Canada GSK Investigational Site, St-Jerome, Quebec, Canada GSK Investigational Site, Santiago, Chile GSK Investigational Site, Santiago, Chile GSK Investigational Site, Bogota, Colombia GSK Investigational Site, Amiens Cedex 1, France GSK Investigational Site, Angers Cedex 9, France GSK Investigational Site, Argenteuil, France GSK Investigational Site, La Roche-Sur-Yon, France GSK Investigational Site, La Tronche, France GSK Investigational Site, Limoges Cedex, France GSK Investigational Site, Melun, France GSK Investigational Site, Paris, France GSK Investigational Site, Pierre-Benite, France GSK Investigational Site, Strasbourg cedex, France GSK Investigational Site, Strasbourg, France GSK Investigational Site, Valenciennes Cedex, France GSK Investigational Site, Aurangabad, India GSK Investigational Site, Aurangabad, India GSK Investigational Site, Hyderabad, India GSK Investigational Site, Kolkata, India GSK Investigational Site, Kolkata, India GSK Investigational Site, Mumbai, India GSK Investigational Site, Nagpur, India GSK Investigational Site, New Delhi, India GSK Investigational Site, Pune, India GSK Investigational Site, Pune, India GSK Investigational Site, Napoli, Campania, Italy GSK Investigational Site, Aichi, Japan GSK Investigational Site, Kanagawa, Japan GSK Investigational Site, Kanagawa, Japan GSK Investigational Site, Osaka, Japan GSK Investigational Site, Saitama, Japan GSK Investigational Site, Tokyo, Japan GSK Investigational Site, Tokyo, Japan GSK Investigational Site, Tokyo, Japan GSK Investigational Site, Tokyo, Japan GSK Investigational Site, Mexico City, Ciudad De Mexico, Mexico GSK Investigational Site, Guadalajara, Jalisco, Mexico GSK Investigational Site, Monterrey, Nuevo Leon, Mexico GSK Investigational Site, Mexico, Mexico GSK Investigational Site, Breda, Netherlands GSK Investigational Site, Den Bosch, Netherlands GSK Investigational Site, Enschede, Netherlands GSK Investigational Site, Nijmegen, Netherlands GSK Investigational Site, Rotterdam, Netherlands GSK Investigational Site, Lima, Peru GSK Investigational Site, Lima, Peru GSK Investigational Site, Lima, Peru GSK Investigational Site, Lima, Peru GSK Investigational Site, Bydgoszcz, Poland GSK Investigational Site, Krakow, Poland GSK Investigational Site, Poznan, Poland GSK Investigational Site, Warszawa, Poland GSK Investigational Site, Wroclaw, Poland GSK Investigational Site, Barnaul, Russian Federation GSK Investigational Site, Chelyabinsk, Russian Federation GSK Investigational Site, Ekaterinburg, Russian Federation GSK Investigational Site, Moscow, Russian Federation GSK Investigational Site, Nizhniy Novgorod, Russian Federation GSK Investigational Site, Omsk, Russian Federation GSK Investigational Site, Perm, Russian Federation GSK Investigational Site, St. Petersburg, Russian Federation GSK Investigational Site, Ufa, Russian Federation GSK Investigational Site, Voronezh, Russian Federation GSK Investigational Site, Benoni, Gauteng, South Africa GSK Investigational Site, Johannesburg, Gauteng, South Africa GSK Investigational Site, Durban, KwaZulu- Natal, South Africa GSK Investigational Site, Panorama,, South Africa GSK Investigational Site, Tygerberg, South Africa GSK Investigational Site, Worcester, South Africa GSK Investigational Site, Barcelona, Spain GSK Investigational Site, L'Hospitalet de Llobregat, Spain GSK Investigational Site, Logrono, Spain GSK Investigational Site, Madrid, Spain GSK Investigational Site, Madrid, Spain GSK Investigational Site, Madrid, Spain GSK Investigational Site, Madrid, Spain GSK Investigational Site, San Sebastian De Los Reyes/Madrid, Spain GSK Investigational Site, Manchester, Greater Manchester, United Kingdom GSK Investigational Site, Liverpool, United Kingdom GSK Investigational Site, Newcastle Upon Tyne, United Kingdom |